Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company's diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33 1 39 46 51 04
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees121
Next Earnings DateN/A
OptionableNot Optionable
Novacyt (LON:NCYT) Frequently Asked Questions
What is Novacyt's stock symbol?
Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."
Has Novacyt been receiving favorable news coverage?
Headlines about NCYT stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novacyt earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Novacyt's key competitors?
Some companies that are related to Novacyt include Nuvo Pharmaceuticals (NRI), Pascal Biosciences (PAS), Synthetic Biologics (SYN), AorTech International (AOR), Synthetic Biologics (SYN), Biopharmx (BPMX), BioPharmX (BPMX), iCo Therapeutics (ICO), Hemispherx BioPharma (HEB), Armata Pharmaceuticals (ARMP), Revive Therapeutics (RVV), Hemogenyx Pharmaceuticals (HEMO), NovaBay Pharmaceuticals (NBY), Netscientific (NSCI) and Redx Pharma (REDX).
Who are Novacyt's key executives?
Novacyt's management team includes the folowing people:
- Mr. Graham Mullis, CEO & Director (Age 56)
- Mr. Anthony Dyer, CFO, Company Sec. & Director
- Ms. Mandy Cowling, Corp. & Investor Relations Mang.
- Ms. Wendy Karban, Group HR Mang.
- Mr. Phillip Sefton, Managing Director of Lab21 Products Division
How do I buy shares of Novacyt?
Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Novacyt's stock price today?
One share of NCYT stock can currently be purchased for approximately GBX 12.50.
How big of a company is Novacyt?
Novacyt has a market capitalization of £2.88 million. Novacyt employs 121 workers across the globe.
What is Novacyt's official website?
How can I contact Novacyt?
The company can be reached via phone at 33 1 39 46 51 04.
MarketBeat Community Rating for Novacyt (LON NCYT)
MarketBeat's community ratings are surveys of what our community members think about Novacyt and other stocks. Vote "Outperform" if you believe NCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
